BRUKINSA (zanubrutinib) capsules, for oral use. Initial U.S. Approval: 2019

Categories: , .

BRUKINSA (zanubrutinib) capsules, for oral use. Initial U.S. Approval: 2019

INDICATIONS AND USAGE
BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
DOSAGE FORMS & STRENGTHS
Capsules: 80 mg
Manufactured By: BeiGene
Prescribing Information URL: Click Here

Access to BRUKINSA ™ (zanubrutinib) capsules: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Zanubrutinib, sold under the brand name Brukinsa, is a medication for the treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy.
It was approved for medical use in the United States in November 2019.
Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor.

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.